Acoltremon (Tryptyr) for Dry Eye Disease

The FDA has approved acoltremon 0.003% ophthalmic solution (Tryptyr – Alcon) for treatment of dry eye disease. Acoltremon is the first transient receptor potential melastatin 8 (TRPM8) thermoreceptor agonist to be approved in the US for this indication.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2025-09-04
DOI
https://doi.org/10.58347/tml.2025.1737a
Primary Topic
Ocular Surface and Contact Lens
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Acoltremon (Tryptyr) for Dry Eye Disease

˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Ocular Surface and Contact Lens
article

Acoltremon (Tryptyr) for Dry Eye Disease

article en

Abstract

The FDA has approved acoltremon 0.003% ophthalmic solution (Tryptyr – Alcon) for treatment of dry eye disease. Acoltremon is the first transient receptor potential melastatin 8 (TRPM8) thermoreceptor agonist to be approved in the US for this indication.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 67(1737)
Openalex Percentile: Top 68%
Ocular Surface and Contact Lens
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Acoltremon (Tryptyr) for Dry Eye Disease · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2025) | TGRS Research Map | TGRS